

REFERENCES

1. World Health Organization. 2006. Fact sheet Number 297 "Cancer". [Online]. Available: <http://www.who.int/mediacentre/factsheets/fs297/en/index.html> (21 June 2006).
2. World Health Organization. 2003. "Global cancer rates could increase by 50% to 15 million by 2020." [Online]. Available: <http://www.who.int/mediacentre/releases/2003/pr27/en/> (21 June 2006).
3. American Cancer Society. 2006. "Cancer Facts & Figures 2006". [Online]. Available: http://www.cancer.org/docroot/STT/stt_0.asp (21 June 2006)
4. National Statistical Office of Thailand. "Number and ratio of deaths population per hundred thousand by cause groups and sex: 1999-2004". [Online]. Available: http://service.nso.go.th/nso/data/data23/stat_23/toc_4/4.3-2.xls (21 June 2006).
5. Statistical Forecasting Bureau, National Statistical Office of Thailand. "Number and ratio of deaths population per hundred thousand by leading cause group and sex in Chiang Mai province: 2002-2003". [Online]. Available: <http://chiangmai.nso.go.th/> (21 June 2006).
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, *et al.* Cancer Statistics, 2006. *CA Cancer J Clin* 2006; 56(2): 106-30.
7. Health Information Unit, Bureau of Health Policy and Strategy. Ministry of Public Health of Thailand. "Number of death and death rates per 100,000 population by sex and causes of death (According to ICD mortality tabulation List 1, the 10th revision) 2000-2004". [Online]. Available: <http://203.157.19.191/death.html> (23 June 2006).
8. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haper DA, *et al.* Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 1990; 60: 509-20.
9. Gessler M, Konig A, Bruns GA. The genomic organization and expression of the WT1 gene. *Genomics* 1992; 12: 807-13.

10. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. *Mol Cell Biol* 1991; 11: 1707-12.
11. Rauscher FJ 3rd. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. *FASEB J* 1993; 7: 896-903.
12. Lewis WH, Yeger H, Bonetta L, Chan HSL, Kang J, Junien C, *et al.* Homozygous deletion of a DNA marker form chromosome 11p13 in sporadic Wilms' tumor. *Genomics* 1988; 3: 25-31.
13. Kikuchi H, Akasaka Y, Najai T, Umezawa A, Iri H, Kato S, *et al.* Genomic changes in the WT gene (WT1) in Wilms' tumors and their correlation with histology. *Am J Pathol* 1992; 140: 781-86.
14. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, *et al.* High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. *Clin Cancer Res* 2002; 8: 1167-71.
15. Sugiyama H. Wilms' tumor gene WT1: Its oncogenic function and clinical application. *Int J Hematol* 2001; 73: 177-87.
16. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, *et al.* WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. *Blood* 1994; 84: 3071-9.
17. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, *et al.* High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. *Blood* 1997; 90: 1217-25.
18. Wang ZY, Qiu QQ, Enger KT, Deuel TF. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. *PNAS. USA* 1993; 90(19): 8896-900.
19. Rauscher FJ 3rd, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. *Science* 1990; 250(4985): 1259-62.
20. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene?. *Int Rev Cytol* 1998; 181: 151-212.

21. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, *et al.* Presence of Wilms, tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* 1995; 9: 1060-7.
22. Guo X, Xu S, Dong Z. *WT1* gene expression in leukemia patients and its correlation with prognosis and multidrug resistance. *Zhonghua Xue Ye Xue Za Zhi* 1999; 20: 69-72.
23. Kelloff, GJ, Crowell JA, Stelle VE, Lubet RA, Malone WA, Boone CW, *et al.* Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. *J Nutr* 2000; 130: 467S-471S.
24. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, *et al.* Chemopreventive and therapeutic effects of curcumin. *Cancer Letters* 2005;223(2):181-90.
25. Nagabhushan M, Bhide SV. Curcumin as an inhibitor of cancer. *J Am Coll Nutr* 1992; 11: 192-98.
26. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene. *Carcinogenesis* 1992; 13(11): 2183-86.
27. Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. *Nutr Cancer* 1992; 17(1): 77-83.
28. Duvoix A, Morceau F, Schnekenburger M, Delhalle S, Galteau MM, Dicato M, *et al.* Curcumin induced cell death in two leukemia cell lines: K562 and Jurkat. *Ann NY Acad Sci* 2003; 1010 (1): 389-92.
29. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. *Biochem Biophys Acta* 1996; 1317: 95-100.
30. Anuchapreeda S, Sadjapong W, Duangrat C, Limtrakul P. The cytotoxic effect of curcumin, demethoxycurcumin and bisdemethoxycurcumin purified from turmeric powder on leukemic cell lines. *Bull Chiang Mai Assoc Med Sci* 2006; 39(1): 60-71.

31. Anuchapreeda S, Limtrakul P, Thanarattanakorn R, Sittpreechacharn S, Chanarat P. Inhibitory effect of curcumin on *WT1* gene expression in patient leukemic cells. *Arch Pharm Res* 2006; 29 (1): 80-87.
32. Anuchapreeda S, Thanarattanakorn R, Sittpreechacharn S Chanarat P, Limtrakul P. Curcumin inhibits *WT1* gene expression in human leukemic K562 cells. *Acta Pharmacologica Sinica* 2006; 27 (3): 360-66.
33. Pannall P and Kotasek D. Genes involved in human cancers. In: McCreanor G and Marshall W, editors. *Cancer and clinical biochemistry*. London: ABC venture publications; 1997. p. 1-15.
34. Gomez A, Salguero G, Garcia H, Aristizabal F, Gutierrez O, Angel LA, *et al.* Detection mutations in the DNA mismatch repair genes of hMLH1 and hMSH2 genes in Colombian families with suspicion of hereditary non-polyposis colorectal carcinoma (Lynch syndrome). *Biomedica* 2005; 25(3): 315-24.
35. Froggatt NJ, Brassett C, Koch DJ, Evans DG, Hodgson SV, Ponder BA, *et al.* Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome. *J Med Genet* 1996; 33(9):726-30.
36. Kariola R, Rævaara TE, Lonngvist KE, Nystrom-Lahti M. Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome. *Hum Mol Genet* 2002; 11(11): 1303-10.
37. Reinartz JJ. Cancer genes. In: Coleman WB and Tsongalis GJ, editors. *The molecular basis of human cancer*. New Jersey: Humana Press Inc; 2002. p. 45-64.
38. Pott P. Chirurgical observations relative to the cancer of the scrotum, London, 1775. *Natl. Cancer Inst. Monograph* 1963; 10: 7-13.
39. Boman BM, Melchert L, Fields JZ. Hereditary cancer. In: Coleman WB and Tsongalis GJ, editors. *The molecular basis of human cancer*. New Jersey: Humana Press Inc; 2002. p. 159-85.
40. Loechler EL, Henry B and Seo KY. Cellular responses to chemical carcinogens. In: Coleman WB and Tsongalis GJ, editors. *The molecular basis of human cancer*. New Jersey: Humana Press Inc; 2002. p. 203-22.
41. Ames BN, Gold LS. The causes and prevention of cancer: the role of environment. *Biotherapy* 1998; 11(2-3): 205-20.

42. Evrard AS, Hemon D, Billon S, Laurier D, Jouglu E, Tirmarche M, *et al.* Childhood leukemia incidence and exposure to indoor radon, terrestrial and cosmic gamma radiation. *Health Phys* 2006; 90(6): 569-79.
43. Rebel H, Karm N, Westerman A, Banus S, van Kranen HJ, de Gruijl FR. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. *Carcinogenesis* 2005; 26(12): 2123-30.
44. Hugo G, Vargas C, Liang J, Kestin L, Wong JW, Yan D. Changes in the respiratory pattern during radiotherapy for cancer in the lung. *Radiother Oncol* 2006; 78(3): 326-31.
45. Finkelstein MM, Kreiger N. Radium in drinking water and risk of bone cancer in Ontario youths: a second study and combined analysis. *Occup Environ Med* 1996; 53(5): 305-11.
46. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. *Dermatol Surg* 2006; 32(4): 481-92.
47. zur Hausen H. Viruses in human cancers. *Science* 1991; 254(5035): 1167-73.
48. Koike K. Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. *J Gastroenterol* 2002; 37 Suppl 13: 55-64.
49. Pili R, Chang J, Muhlhauser J, Crystal RG, Capogrossi MC, Passaniti A. Adenovirus-mediated gene transfer of fibroblast growth factor-1: angiogenesis and tumorigenicity in nude mice. *Int J Cancer* 1997; 73(2): 258-63.
50. Kawa K. Epstein-Barr virus-associated diseases in humans. *Int J Hematol* 2000; 71(2): 108-17.
51. Eling DJ, Johnson PA, Sharma S, Tufaro F, Kipps TJ. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. *Gene Ther* 2000; 7(14): 1210-6.
52. Pogo BG, Holland JF. Possibilities of a viral etiology for human breast cancer: A review. *Biol Trace Elem Res* 1997; 56(1): 131-42.
53. Ravandi F, Verma A, Ridgeway J, Pursell K. Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. *Leuk Res* 2003; 27(9): 853-7.

54. Peretti G, Torri G, Marinoni EC, Facchini R, Scaglione P, Mantovani G. Experimental osteosarcoma in the mouse, induced by Moloney's murine sarcoma virus. *Ital J Orthop Traumatol* 1980; 6(2): 255-68.
55. Demers DM, Fukushima S, Cohen SM. Effect of sodium saccharin and L-tryptophan on rat urine during bladder carcinogenesis. *Cancer Res* 1981; 41(1): 108-12.
56. Li M. Studies on pickled vegetables and cause of esophageal cancer in Linxian. I. Experiments on carcinogenicity of pickled vegetables. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 1990; 12(5): 353-8.
57. Hoppe-Seyler F and Butz K. Viral mechanisms of human carcinogenesis. In: Coleman WB and Tsongalis GJ, editors. *The molecular basis of human cancer*. New Jersey: Humana Press Inc; 2002. p. 233-50.
58. Proia NK, Paszkiewicz GM, Nasca MA, Franke GE, Pauly JL. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer-a review. *Cancer Epidemiol Biomarkers Prev* 2006; 15(6): 1061-77.
59. Harris JE, Thun MJ, Mondul AM, Calle EE. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. *BMJ* 2004; 328(7431): 72.
60. Sarna L, Cooley ME, Danao L. The global epidemic of tobacco and cancer. *Semin Oncol Nurs* 2003; 19(4): 233-43.
61. Momas I, Daures JP, Festy B, Bontoux J, Gremy F. Bladder cancer and black tobacco cigarette smoking. Some results from a French case-control study. *Eur J Epidemiol* 1994; 10(5): 599-604.
62. Colangelo LA, Gapstur SM, Gann PH, Dyer AR. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. *Cancer* 2004; 100(2): 223-4.
63. Huo TI, Wu JC, Lee SD. Are alcohol, tobacco and obesity genuine risk factors for hepatocellular carcinoma? *J Hepatol* 2005; 42(6): 941.
64. Clavel J, Bellec S, Rebouissou S, Menegaux F, feunteun J, Bonaiti-Pellie C, *et al*. Childhood leukemia, polymorphisms of metabolism enzyme genes, and

- interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. *Eur J Cancer Prev* 2005; 14(6): 531-40.
65. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. *J Hepatol* 2005; 42(2): 218-24.
 66. Lin Y, Kikuchi S, Tamakoshi K, Wakai K, Kondo T, Niwa Y, *et al.* Prospective study of alcohol consumption and breast cancer risk in Japanese woman. *Int J Cancer* 2005; 116(5): 779-83.
 67. Maeda M, Nagawa H, Maeda T, Koike H, Kasai H. Alcohol consumption enhances liver metastasis in colorectal carcinoma patients. *Cancer* 1998; 83(8): 1483-8.
 68. Virchow R. Weisses blut. *Frariep's Notizen* 1845; 36: 151.
 69. Bennett JM. Two cases of disease and enlargement of the spleen in which death took place from the presence of purulent matter in the blood. *Edinburgh Med Surg J* 1845; 64: 413.
 70. McKenzie SB. Textbook of hematology. 2nd ed. Maryland: Williams & Wilkins; 1996. 733 pp.
 71. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. *Br J Haematol* 1976; 33(4): 451-58.
 72. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* A variant form of hypergranular promyelocytic leukemia (M3). *Br J Haematol* 1980; 44(1): 169-70.
 73. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposal revised criteria for classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. *Ann Intern Med.* 1985; 103(4): 620-5.
 74. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). *Ann Intern Med.* 1985; 103(3): 460-2.

75. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposals for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). *Br J Haematol* 1991; 78: 325-29.
76. First MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias. *Cancer Genetics and Cytogenetics* 1986; 23: 189-97.
77. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. *Cancer Genetics and Cytogenetics* 1988; 30: 1-15.
78. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. *Br J Haematol* 1988; 68: 487-94.
79. Bennett JM, Juliusson G, Mecucci C. Meeting report. Morphologic, immunologic, and cytogenetic classification of the chronic (mature) B and T lymphoid leukemias: Fourth Meeting of the MIC Cooperative Study Group. *Cancer Res* 1990; 50: 2212.
80. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, *et al.* World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissue: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol* 1999; 17: 3835-49.
81. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. *Int J Hematol* 2000; 72: 131-3.
82. Brunning RD, Matutes E, Harris NL. Acute myeloid leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001: 75-108.
83. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, *et al.* The World Health Organization classification of hematological malignancies. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. *Mod Pathol* 2000; 13: 193-207.

84. Keenan FM, Barnett D, Reilly JT. Clinico-pathological features of minimally differentiated acute myeloid leukemia (AML-M0). *BrJ Haematol* 1992; 81(3): 458-9.
85. Venditti A, Del Poeta G, Stasi R, Masi M, Bruno A, Buccisano F, *et al.* Minimally differentiated acute myeloid leukemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. *Br J Haematol* 1994; 88(4): 784-93.
86. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuyneck H, Van Orshoven A, *et al.* Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. *Blood* 1995; 85(12): 3688-94.
87. Cohen PL, Hoyer JD, Kurtin PJ, Dewald GW, Hanson CA. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. *Am J Clin Pathol* 1998; 109(1): 32-8.
88. Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA, *et al.* The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. *Leukemia* 1999; 13(10): 1513-8.
89. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox MC, Stasi R, *et al.* Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. *Blood* 1997; 89(2): 621-9.
90. Huang SY, Tang JL, Jou ST, Tsay W, Hu CH, Lin DT, *et al.* Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. *Leukemia* 1999; 13(10): 1506-12.
91. Mitelman F. Catalog of Chromosome Aberrations in Cancer, Vol. 6. Progress and Topics in Cytogenetics (ed. By Sandberg AA). Alan R. Liss, New York.
92. McKenna RW. Multifaceted approach to the diagnosis and classification of acute leukemias. *Clin Chem* 2000; 46: 1252-9.
93. Morrison VA. Chronic leukemias. *CA cancer J Clin* 1994; 44: 353-77.

94. Brincker H. Population-based age- and sex-specific incidence rates in the 4 main types of leukemia. *Scand J Haematol* 1982; 29: 241-9.
95. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. *Blood* 1987; 70(5): 1584-8.
96. Rerkamnuaychoke B, kangwanpong D, Jootar S, Puranakitstha C. Detection of BCR/ABL fusion gene in CML: a preliminary report. *Southeast Asian J Trop Med Public Health* 1995; 26 (Suppl 1): 197-200.
97. Druker BJ, Lydon NB. Lessons learned form the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. *J Clin Invest* 2000; 105: 3-7.
98. Cervantes F, Lopez-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinico-hematological criteria for the accelerated phase of chronic myeloid leukemia. *Eur J Haematol* 1996; 57: 286-91.
99. Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase and probabilities of survival and relapse. *Br J Haematol* 1997; 99: 30-35.
100. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. *Blood* 1993; 82: 691-7033.
101. Cortes JE, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review. *Am J Med* 1996; 100: 555-70.
102. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002; 100: 2292-302.
103. Byrd JC, Stilgenbauer S, Film IW. Chronic lymphocytic leukemia. *Hematology* 2004; 163-83.
104. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. *Semin Oncol* 1998; 25: 42.
105. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. *Rec Clin Exp Hematol* 2000; 4: 5-21.
106. Harris NL. Mature B-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and

Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001: 127-30, 138-41.

107. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposals for the classification of chronic (mature) B and T lymphoid leukemias. *J Clin Pathol* 1989; 42: 567-584.
108. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, *et al.* A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. *Blood* 1994; 84: 1361-92.
109. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, *et al.* Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. *Blood* 1997; 89: 4501-13.
110. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Lewy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. *Blood* 1975; 46(2): 219-34.
111. Binet JL, Auguier A, Dighiero G, Chastang C, Piguët H, Goasguen J, *et al.* A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer* 1981; 48: 198-206.
112. Farhi DC, Chai CC, Edelman AS, Parveen T, Thi Vo TL. Risk factors for hematopoietic neoplasia. In: Farhi DC, editors. Pathology of bone marrow and blood cells. Philadelphia: Lippincott Williams & Wilkins; 2004. p.189-200.
113. Ross JA, Robinson LL. MLL rearrangements in infant leukemia: is there a higher frequency in female? *Leuk Res* 1997; 21: 793-95.
114. Jackson N, Menon BS, Zarina W, Zawawi N, Naing NN. Why is acute leukemia more common in males? A possible sex-determined risk linked to the ABO blood group genes. *Ann Hematol* 1999; 78: 233-6.
115. Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. *Leuk Lymphoma* 2002; 43: 467-77.
116. Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Hertenstein B, Schipper RF, *et al.* HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. *Leukemia* 2000; 14: 859-62.

117. Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, *et al.* HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. *Blood* 1999; 93: 3863-5.
118. Horwitz M, Goode EL, Jarvik GP. Anticipation in familial leukemia. *Am J Hum Genet* 1996; 59: 990-8.
119. Kwong YL, Ng MH, Ma SK. Familial acute myeloid leukemia with monosomy7: late onset and involvement of a multipotential progenitor cell. *Cancer Genet Cytogenet* 2000; 116: 170-3.
120. Goi K, Sugita K, Nakamura M, Miyamoto N, Karakida N, Iijima K, *et al.* Development of acute lymphoblastic leukemia with translocation (4;11) in a young girl with familial pericentric inversion 12. *Cancer Genet Cytogenet* 1999; 110: 124-7.
121. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukemia and solid tumours in individuals with Down's syndrome. *Lancet* 2000; 355: 165-9.
122. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, *et al.* Mutations of the *NF1* gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. *Blood* 1998; 92: 267-72.
123. Felix CA, Megonigal MD, Chervinsky DS, Leonard DG, Tsuchida N, Kakati S, *et al.* Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. *Blood* 1998; 91: 4451-6.
124. Krajcinovic M, Richer C, Sinnott H, Labuda D, Sinnott D. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 557-62.
125. Sugita K, Taki T, Hayashi Y, Shimaoka H, Kumazaki H, Inoue H, *et al.* MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16) (q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia. *Genes Chromosomes Cancer* 2000; 27: 264-9.
126. Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D. Chronic myeloid leukemia with marked thrombocytosis in a patient with thalassemia major: complete haematological remission under the

- combination of hydroxyurea and anagrelide. *Br J Haematol* 2002; 116(1): 155-7.
127. Sotomayor EA, Glasser L. Acute lymphoblastic leukemia in sickle cell disease. *Arch Pathol Lab Med* 1999; 123: 745-6.
128. Biggs BG, Vaughan W, Colombo JL, Sanger W, Purtilo DT. Cystic fibrosis complicated by acute leukemia. *Cancer* 1986; 57: 2441-3.
129. Rizzari C, Conter V, Jankovic M, D'Angelo P, Masera G, Costantini D, *et al.* Acute lymphoblastic leukemia in a child with cystic fibrosis. *Haematologica* 1992; 77: 427-9.
130. Ariad S, Argov S, Manor E, yermiahu T, Kedar I. Acute blast crisis with EBV-infected blasts, in a patient with chronic myeloid leukemia, and vasculitis. *Leuk Lymphoma* 2000; 37: 431-5.
131. Sakajiri S, Mori K, Isobe Y, Kawamata N, Oshimi K. Epstein-Barr virus associated T-cell acute lymphoblastic leukemia. *Br J Haematol* 2002; 117: 127-9.
132. Au WY, Ma ES, Kwong YL. Acute myeloid leukemia precipitated by dengue virus infection in a patient with hemoglobin H disease. *Hematologica* 2001; 86: E17.
133. Gentile G, Mele A, Monarco B, Vitale A, Pulsoni A, Visani G, *et al.* Hepatitis B and C viruses, human T-cell lymphotropic virus type I and II, and leukemia: a case-control study. The Italian Leukemia Study Group. *Cancer Epidemiol Biomarkers Prev* 1996; 5: 227-30.
134. Yoshikawa T, Kobayashi I, Asano Y, Nakashima T, Yazaki T, Kojima A, *et al.* Clinical features of primary human herpesvirus-6 infection in an infant with acute lymphoblastic leukemia. *Am J Pediatr Hematol Oncol* 1993; 15: 424-6.
135. Hentrich M, Rockstroh J, Sandner R, Brack N, Hartenstein R. Acute myelogenous leukemia and myelomonocytic blast crisis following polycythemia vera in HIV positive patients: report of cases and review of the literature. *Ann Oncol* 2000; 11: 195-200.
136. Kawachi Y, Watanabe A, Sakamoto Y, Abe T, Uchida T, Sacho M, *et al.* Acute myeloblastic leukemia associated with an intermediate state between the

- healthy carrier state and adult T-cell leukemia. *Leuk Lymphoma* 1995; 16: 505-9.
137. Dockerty JD, Skegg DC, Elwood JM, Herbison GP, Becroft DM, Lewis ME. Infections, vaccinations, and the risk of childhood leukemia. *Br J Cancer* 1999; 80: 1483-9.
138. Sitar G, Balduini CL, Manenti L, Castello A, Balanzin D, Ascari E. Possible evolution of human parvovirus B19 infection into erythroleukemia. *Haematologica* 1999; 84: 957-9.
139. Kelly SJ, Gibbs T, Cheetgam CH. Acute myelomonocytic leukemia following atypical congenital rubella. *J Clin Pathol* 1993; 46: 764-5.
140. Vianna NJ, Polan AK. Childhood lymphatic leukemia: prenatal seasonality and possible association with congenital varicella. *Am J Epidemiol* 1976; 103: 321-32.
141. Murray JC, Bomgaars LR, Carcamo B, Mahoney DH Jr. Lymphoid malignancies following Kawasaki disease. *Am J Hematol* 1995; 50: 299-300.
142. Schuz J, Kaletsch U, Meinert R, Kaatsch P, Michaelis J. Association of childhood leukemia with factors related to the immune system. *Br J Cancer* 1999; 80: 585-90.
143. Abbas Z, Malik I, Khan A. Sequential induction of aplastic anemia and acute leukemia by chloramphenicol. *J Pak Med Assoc* 1993; 43: 58-9.
144. Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, *et al.* High risk of leukemia after short-term dose-intensive chemotherapy for rheumatoid arthritis. *J Clin Oncol* 1998; 16: 3016-20.
145. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, *et al.* Predictors of therapy-related leukemia and myelodysplasia following autologous bone marrow transplantation for lymphoma: an assessment of risk factors. *Blood* 2000; 95: 1588-93.
146. Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, *et al.* Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. *Bone marrow Transplant* 2001; 28: 705-7.

147. Fasching K, Panzer S, Haas OA, Marschalek R, Gadner H, Panzer-Grumayer ER. Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia. *Blood* 2000; 95: 2722-4.
148. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. *PNAS USA* 2000; 97:4790-5.
149. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. *Leukemia* 1997; 11: 1661-4.
150. Cline M. The molecular basis of leukemia. *N Engl J Med* 1994; 330: 328-36.
151. Mitelman F and Heim S. Quantitative acute leukemia cytogenetics. *Genes Chromosomes Cancer* 1992; 5: 57-66.
152. Rabbitts T. Translocations, master genes, and differences between the origins of acute and chronic leukemias. *Cell* 1991; 67: 641-4.
153. Thandle S and Aplan P. Molecular biology of acute lymphocytic leukemia. *Semin Oncol* 1997; 24: 45-56.
154. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, *et al.* chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses *RAR α* with a novel putative transcription factor, *PML*. *Cell* 1991; 66: 663-74.
155. de The H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A. The *PML-RAR α* fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991; 66: 675-84.
156. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. *Nature* 1985; 315: 758-61.
157. Bos JL, Verlaan-de Varies M, van der Eb AJ, Janssen JW, Delwel R, Lowenberg B, *et al.* Mutations in N-ras predominate in acute myeloid leukemia. *Blood* 1987; 69: 1237-41.

158. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of *RAS* genes in human hematologic malignancies determined by DNA amplification and direct sequencing. *Blood* 1990; 75: 1684-90.
159. Ahuja HG, Jat P, Foti A, Bar-Eli M, Cline M. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. *Blood* 1991; 78: 3259-68.
160. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. *Blood* 1994; 84: 2391-411.
161. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, *et al.* Mutations of the p53 and *ras* genes in childhood t(1;19)-acute lymphoblastic leukemia. *Blood* 1995; 85: 2546-52.
162. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, *et al.* Mutations of the p53 gene in acute myeloid leukemia. *Br J Haematol* 1992; 80: 178-83.
163. Kitagawa M, Yoshiad S, Kuwata T, Tanizawa T and Kamiyama R. p53 expression in myeloid cells of myelodysplastic syndromes association with evolution of overt leukemia. *Am J Pathol* 1994; 145: 338-44.
164. John RW, Palsson BO. Human Cell Culture; Cancer Cell Lines Part 3: Leukemia and Lymphomas. Boston: Kluwer Academic Publishers; 2000. 397 pp.
165. Gey GO, Coffman WD, Kubicek MT. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. *Cancer Res* 1952; 12: 264-5.
166. Pulvertaft RJV. Cytology of Burkitt's tumor (African lymphoma). *Lancet* 1964; i: 238-40.
167. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. *J Natl Cancer Inst* 1972; 49(3): 891-5.
168. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. *Blood* 1975; 45(3): 321-34.
169. Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. *Leuk Res* 1979; 3(6): 363-70.

170. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukemia cell line K562. *Nature* 1979; 278(5702): 364-5.
171. Epatein AL, Henle W, Henle G, Hewetson JF, Kaplan HS. Surface marker characteristics and Epstein-Barr virus studies of two established North American Burkitt's lymphoma cell lines. *PNAS USA* 1976; 73(1): 228-32.
172. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. *Int J Cancer* 1977; 19(5): 621-6.
173. Gillis S, Watson J. Biochemical and biological characterization of lymphocyte regulator molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. *J Exp Med* 1980; 152(6): 1709-19.
174. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. *Nature* 1977; 270(5635): 347-9.
175. Coppes MJ, Campbell CE, Williams BR. The role of WT1 in Wilms tumorigenesis [review]. *FASEB J* 1993; 7: 886-95.
176. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, *et al.* WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. *Science* 1993; 262: 2057-9.
177. Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y, Smith PJ. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript. *Hum Mutat* 1995; 5: 221-7.
178. Little M, Wells CA. Clinical overview of WT1 gene mutations [review]. *Hum mutat* 1997; 9: 209-25.
179. Madden SL, Cook DM, Rauscher FJ 3rd. A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein. *Oncogene* 1993; 8(7): 1713-20.
180. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, *et al.* WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. *J Biol Chem* 1995; 270: 10878-84.

181. Englert C, Vidal M, Maheswaran S, Ge Y, Ezzell R, Isselbacher KJ, *et al.* Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. *PNAS USA* 1995; 92: 11960-4.
182. Wang Z, Qiu Q, Gurrieri M, Huang J, Deuel TF. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. *Oncogene* 1995; 10: 1243-7.
183. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. *PNAS USA* 1992; 89: 10984-88.
184. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. *J Biol Chem* 1993; 268: 21271-5.
185. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. *Science* 1992; 257: 674-8.
186. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, *et al.* WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. *EMBO J* 1995; 14: 4662-75.
187. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor- α gene by the Wilms tumor suppressor gene product, wt1. *Oncogene* 1995; 10: 1125-9.
188. McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myc gene by WT1 protein in T and B cell lines. *J Biol Chem* 1995; 270: 23785-9.
189. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. *Cancer Res* 1995; 55: 5386-9.
190. Zhang X, Xing G, Saunders GF. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1. *Anti-cancer Res* 1999; 19: 1641-8.
191. Guan LS, Rauchman M, Wang ZY. Introduction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. *J Biol Chem* 1998; 273: 27047-50.

192. Kim J, Prawitt D, Bardeesy N, Torban E, Vicaner C, Goodyer P, *et al.* The Wilms' tumor suppressor gene (WT1) product regulates Dax-1 gene expression during gonadal differentiation. *Mol Cell Biol* 1999; 19(3): 2289-99.
193. Mayo MW, Wang CY, Drouin SS, Madrid KV, Marshall AF, Reed JC, *et al.* WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. *EMBO J* 1999; 18(14): 3990-4003.
194. Brown KW, Malik KTA. The molecular biology of Wilms' tumour. Expert Review in Molecular Medicine. 2001. [Online] Available: <http://www-ermm.cbcu.cam.ac.uk/01003027h.htm>.
195. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, *et al.* Alternative splicing and genomic structure of the Wilms' tumor gene WT1. *PNAS USA* 1991; 88: 9618-22.
196. Morris JF, Madden SL, Tournay OE, Cook DM, Sukhatme VP, Rauscher FJ 3rd. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. *Oncogene* 1991; 6(12): 23339-48.
197. Kent J, Coriat AM, Sharpe PT, Hastie ND, Van Heyningen V. The evolution of WT1 sequence and expression pattern in the vertebrates. *Oncogene* 1995; 11: 1781-92.
198. Sharma PM, Bowman M, Madden SL, Rauscher FJ, Sukumar S. RNA editing in the Wilms' tumor susceptibility gene, WT1. *Genes Dev* 1994; 8: 720-31.
199. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. *J Biol Chem* 1996; 271: 8646-54.
200. Scharnhorst V, Dekker P, van der Eb AJ, Jochemsen AG. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. *J Biol Chem* 1999; 274: 23456-62.
201. Bickmore WA, Oghene K, Little MH, Seawright A, Van Heyningen V, Hastie ND. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. *Science* 1992; 257(5067): 235-7.
202. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. *Gene* 2001; 273: 141-61.

203. Armstrong JF, Pritchard-Jones K, Bickmor WA, Hastie ND, Bard JBL. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. *Mech Dev* 1992; 40: 85-97.
204. Rackley RR, Flenniken AM, Kuriyan NP, Kessler PM, Stoler MH, Williams BRG. Expression of the Wilms, tumor suppressor gene WT1 during mouse embryogenesis. *Cell Growth Differ* 1993; 4: 1023-31.
205. Kreidberg JA, Soriola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. *Cell* 1993; 74: 679-91.
206. Gessler M, Proustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. *Nature* 1990; 343(6260): 774-8.
207. Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, *et al.* Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. *Cancer Invest.* 1993; 11(4): 393-9.
208. Viel A, Giannini F, Capozzi E, Canzonieri V, Scarabelli C, Gloghini A, *et al.* Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. *Int J Cancer* 1994; 57(4): 515-21.
209. Campbell CE, Kuriya NP, Rackley RR, Caulfield MJ, Tubbs R, Finke J, *et al.* Constitutive expression of the Wilms' tumor suppressor gene (WT1) in renal cell carcinoma. *Int J Cancer* 1998; 78(2):182-8.
210. Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. *Cancer Res* 1994; 54: 3101-6.
211. Langerak AW, Williamson KA, Miyagawa K, Hagemeijer A, Versnel MA, Hastie ND. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. *Genes Chromosomes Cancer* 1995; 12: 87-96.
212. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfı T, Maurer J, *et al.* Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. *Int J Cancer* 1994; 59(1): 78-82.

213. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. *Cancer Res* 1994; 54: 2837-40.
214. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. *PNAS USA* 1997; 94: 8132-37.
215. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, *et al.* Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. *Jpn J Cancer Res* 1999; 90(2): 194-204.
216. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, *et al.* Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. *J Cancer Res Clin Oncol* 2000; 126(4): 226-32.
217. Harada Y, Nonomura N, Nishimura K, Tamaki H, Takahara S, Miki T, *et al.* The WT1 expression in human testicular germ cell tumors. *Mol Urol* 1999; 3: 357-63.
218. Miwa H, Beran M, Saunders GF. Expression of Wilms' tumor gene (WT1) in human leukemias. *Leukemia* 1992; 6: 405-09.
219. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. *Leukemia* 1993; 7: 970-77.
220. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, *et al.* High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. *Blood* 1997; 90(3): 1217-25.
221. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.
222. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, *et al.* Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* 1995; 9(6): 1060-7.
223. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. *Oncogene* 1996; 12: 1005-14.

224. Wu YJ, Fraizer GC, Saunders GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. *J Biol Chem* 1995; 270: 5944-49.
225. McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myc gene by WT1 protein in T and B cell lines. *J Biol Chem* 1995; 270(40): 23785-9.
226. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. *Exp Hematol* 1997; 25(9): 945-50.
227. Phelan SA, Linberg C, Call KM. Wilms, tumor gene, WT1, mRNA is down regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. *Cell Growth Differ* 1994; 5: 677-86.
228. Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. *J Ethnopharmacol* 1999; 67(1): 1-6.
229. <http://www.gpo.or.th/rdi/oldmedicine/product2.html>
230. http://www.thaifloriade.thaigov.net/hort_cd/herb/html/07_Tumeric2.htm
231. http://www.nlm.nih.gov/medlineplus/druginfo/natural/img/turmeric_cr.jpg
232. Farnsworth NR, Bunyapraphatsara N. Thai Medicinal Plants, recommended for primary health care system. Medicinal Plant Information Center, Faculty of Pharmacy, Mahidol University, Sri-ayuthaya rode, Bangkok, Thailand, Prachachon Co. Ltd. 402 pp.
233. Chen CM, Fang HC. Chemical analysis of the active principles of Curcuma species. In: Modern Treatise on Chinese Herbal Medicines. 1997; 3: 95-105.
234. Nethsingha C, Paskaranathan U. Turmeric: a literature survey. Ceylon Institute of scientific and Industrial Research, Srilanka. 1976; 1-28.
235. Lantz RC, Chen GJ, solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. *Phytomedicine* 2005; 12(6-7): 445-52.
236. Miquel J, Bernd A, Sempere JM, Diaz-Alperi J, Ramirez A. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. *Arch Gerontol Gderiatr* 2002; 34(1): 37-46.

237. Kim KJ, Yu HH, Cha JD, Seo SJ, Choi NY, You YO. Antibacterial activity of *Curcuma longa* L. against methicillin-resistant *Staphylococcus aureus*. *Phytother Res* 2005; 19(7): 599-604.
238. Wuthi-udomlert M, Grisanapan W, Luanratana O, Caichompoo W. Antifungal activity of *Curcuma longa* grown in Thailand. *Southeast Asian J Trop Med Public Health* 2000; 31(Suppl 1): 178-82.
239. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. *Biochem Pharmacol* 1995; 49(8): 1165-70.
240. Polasa K, Raghuram TC, Krishna TP, Krishnaswamy K. Effect of turmeric on urinary mutagens in smokers. *Mutagenesis* 1992; 7(2): 107-9.
241. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res* 2003; 23(1A): 363-98.
242. Krishnamurthy N, Mathew AG, Nambudiri ES, Shivashanker S, Lewis YS, Natarajan CP. Tropical Science, London Her Majesty's Stationary office. 1976; 18: 37-45.
243. The MERCK Index, 9th ed. MERCK & CO. Inc. 1976; 384.
244. Dictionary of organic compound, 4th ed. Richard Clay Ltd. 1965; 2: 262.
245. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-I gene by natural curcuminoids. *BMC cancer* 2004; 4: 13.
246. Asai A, Nakagawa K, Miyazawa T. Antioxidative effects of turmeric, rosemary and capsicum extracts on membrane phospholipids peroxidation and liver lipid metabolism in mice. *Biosci Biotechnol Biochem* 1999; 63 (12): 2118-22.
247. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, *et al.* Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. *Atherosclerosis* 1999; 147: 371-8.
248. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. *Biochem Pharmacol* 1995; 49: 1165-70.
249. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. *Biochem Biophys Res Commun* 1996; 226: 1-7.

250. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. *Proc Natl Acad Sci USA* 1993; 90: 1839-42.
251. Kang BY, Song YJ, Kim KM, Choe YK, Hwang SY, Kim TS. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. *Br J Pharmacol* 1999; 128: 380-4.
252. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). *Cancer Chemother Pharmacol* 2006; 57(3): 376-88.
253. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. *Biochem Pharmacol* 1995; 49: 1551-6.
254. Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. *Int J Immunopharmacol* 1999; 21: 745-57.
255. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, *et al.* The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. *Thromb Haemast* 1997; 77: 772-82.
256. Kuner P, Schubnel R, Hertel C. Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. *J Neurosci Res* 1998; 54: 798-804.
257. Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors *EGR-1*, *AP-1* and *NF-kappa B*. *Artheroscler Thromb Vasc Biol* 1997; 17: 3406-13.
258. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). *J Biol Chem* 1995; 270: 24995-5000.
259. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. *Oncogene* 1998; 17: 173-8.
260. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix


- metalloproteinases in synovial fibroblasts of rheumatoid arthritis. *J Biol Chem* 2000; 275: 444-50.
261. Hanif R, Qiao L, Shiff SJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation, and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. *J Lab Clin Med* 1997; 130: 576-84.
262. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. *Anticancer Res* 1999; 19: 3675-80.
263. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized HIH 3T3 and malignant cancer cell lines. *Nutr Cancer* 1996; 26: 111-20.
264. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. *J Invest Dermatol* 1998; 111: 656-61.
265. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. *Crit Rev Food Sci Nutr* 2004; 44(2): 97-111.
266. Deshpande SS, Maru GB. Effects of curcumin on the formation of benzo[a]pyrene derived DNA adducts in vitro. *Cancer Lett* 1995; 96: 71-80.
267. Huang MT, Ma W, Lu YP, Chang RL, Fisher C, Manchand PS, *et al.* Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. *Carcinogenesis* 1995; 16: 2493-7.
268. Lin JK, Chen YC, Huang YT, Lin-Shiau SY. Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. *J Cell Biochem Suppl* 1997; 29: 39-48.
269. Limtrakul P, Anuchapreeda S, Lipigorngoson S, Dunn FW. Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. *BMC cancer* 2001; 1:1.

270. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. *Clin Cancer Res* 1999; 5: 1884-91.
271. Limtrakul P, Chearwae W, Anuchapreeda S. The effects of curcumin on the proliferation of cancer cell lines. *Chiang Mai Med Bull* 1999; 38: 55-61.
272. Rashmi R, Santhosh Kumar TR, Karunakaran D. Human colon cancer cells differ in their sensitivity to curcumin-induced apoptosis and heat shock protects them by inhibiting the release of apoptosis-inducing factor and caspases. *FEBS Letters* 2003; 538: 19-24.
273. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. *Cancer Letters* 2004; 208: 163-70.
274. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul P. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. *Biochem Pharmacol* 2002a; 64: 573-82.
275. Anuchapreeda S, Muangmoonchai R, Limtrakul P. Effect of curcuminoids on *MDR1* gene promoter activity in human cervical carcinoma cells. *Chiang Mai Med Bull* 2002b; 41(4): 189-202.
276. Nagabhushan M, Bhide SV. Curcumin as an inhibitor of cancer. *J Am Coll Nutr* 1992; 11: 192-98.
277. Banjerdpongchai R, Wilairat P. Curcumin induced apoptosis in HL-60 cells: The effect of antioxidants. Proceedings of the International Colloquium 2004, Health Benefits and Applications of Polyphenols; 2004 Nov 25-26; Chiang Mai, Thailand. 2004. p.3-9.
278. Anuchapreeda S, Chanarat P, Thanarattanakorn P, Sittipreechacharn S, Limtrakul P. Effect of turmeric curcuminoids on *WT1* gene expression in patient leukemic cells and K562 cell line. Proceedings of the International Colloquium 2004, Health Benefits and Applications of Polyphenols; 2004 Nov 25-26; Chiang Mai, Thailand. 2004. p.40-51.
279. Anuchapreeda S, Wikan N, Tima S, Thanarattanakorn R, Sittipreechacharn S, Limtrakul P. Effect of curcumin on *WT1* gene expression in human leukemic cells. *J Med Tech Assoc Thailand* 2005; 33 (3): 1252-1264.

280. Rao DS, Sekhara NC, Satyanarayana MN, Srinivasan M. Effect of curcumin on serum and liver cholesterol levels in the rat. *J Nutr* 1970; 100: 1307-15.
281. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric: acute toxicity studies in rats, guinea pigs and monkeys. *Indian J Exp Biol* 1980; 18: 73-5.
282. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. *J Immunol Methods* 1983; 65: 55-63.
283. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-Phenol reagents. *J Biol Chem* 1951; 193: 265-75.
284. Kaufmann SH, Ewing CM, Shaper JH. The erasable Western blot. *Anal Biochem* 1987; 161(1): 89-95.
285. Kaufmann SH, Kellner U. Erasure of western blots after autoradiographic or chemiluminescent detection. *Methods Mol Biol* 1998; 80: 223-35.
286. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, *et al.* Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. *Blood* 1996; 88(6): 2267-78
287. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, *et al.* Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. *Blood* 1997; 89(4): 1405-12.
288. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyaki S, *et al.* Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. *Blood* 1996; 88(11): 4396-8.
289. Wu Y, Fraizer GC, Saunders GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. *J Biol Chem* 1995; 270(11): 5944-9.
290. Ye Y, Raychaudhuri B, Gurney A, Cambell CE, Williams BR. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. *EMBO J* 1996; 15(20): 5606-15.
291. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, *et al.* Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. *Biochem Pharmacol* 2003; 66(8): 1475-83.

292. Chen WH, Chen Y, Gu JX, He J. Effect of curcumin on STAT5 signaling molecule in K562 cells. *Chin J Hematol* 2004; 25: 151-3.
293. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, *et al.* Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. *Blood* 1998; 91(8): 2969-76.
294. <http://www.curcuminoids.com/structure.htm>
295. Lee E, Surh YJ. Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. *Cancer Lett* 1998; 134(2): 163-8.
296. Simon A, Allais DP, Duroux JL, Basly JP, Durand-Fontanier S, Delage C. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. *Cancer Lett* 1998; 129: 111-6.
297. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. *Blood* 1994; 83(7): 1876-82.
298. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, *et al.* Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. *Blood* 1996; 87(7): 2878-84.
299. Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. *Cancer Res* 1997; 57(8): 1429-34.
300. Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman DA. Cyclin E is a target of WT1 transcriptional repression. *J Biol Chem* 2002; 277(22): 19627-32.
301. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The wilms tumor suppressor gene *WT1* induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. *FEBS Lett* 1997; 409: 41-45.
302. Kunchady E, Rao MNA. Oxygen radical scavenging activity of curumin. *Int J Pharm* 1990; 58(3): 237-40.
303. Soudamini KK, Kuttan R. Inhibition of chemical carcinogenesis by curcumin. *J Ethnopharmacol* 1989; 27(1-2): 277-33.

304. Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y. Natural antioxidants. III. Antioxidative components isolated from rhizome of *Curcuma longa* L. *Chem Pharm Bull* 1985; 33(4): 1725-8.
305. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from *Curcuma longa*. *Phytomedicine* 2000; 7(4): 303-8.
306. Ahsan H, Parveen N, Khan NU, Hadi SM. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. *Chem Biol Interact* 1999; 121(2): 161-75.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright © by Chiang Mai University
All rights reserved